Novartis gained support for its drug Zarxio back in January, when an FDA panel recommended the agency approve the drug. Amgen, which makes the original drug Neupogen, is developing a biosimilar as well, and has been supportive of the competition. ExpressScripts estimates that the generic version could save cancer patients a total of $5.7 billion over the next 10 years.
The Wall Street Journal lists a number of other biosimilars that are in development or awaiting FDA approval. Overall, there are at least 11 potential biosimilars seeking FDA approval: If all get approved, patients could save $250 billion over the next decade.
Biosimilars have been available in Europe since 2006. In our “Year In Ideas”package, Popular Science predicted that 2015 would be the year biosimilars would hit finally the U.S. market, and we're happy to report that we were spot on.
source: popsci.com Lydia Ramsey